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Background: Eosinophils play important roles in the development of asthma exacerbation. Viral infection
is a major cause of asthma exacerbation, and the expression of IFN-g-inducible protein of 10 kDa (IP-10)
and cysteinyl leukotrienes (cysLTs) is up-regulated in virus-induced asthma. As b2-adrenergic agonists,
such as formoterol or salbutamol, are used to treat asthma exacerbation, we examined whether for-
moterol or salbutamol could modify eosinophil functions such as adhesiveness, particularly those acti-
vated by cysLTs or IP-10.
Methods: Eosinophils were isolated from the blood of healthy subjects and were pre-incubated with
either formoterol or salbutamol, and subsequently stimulated with IL-5, LTD4, or IP-10. Adhesion of
eosinophils to intercellular cell adhesion molecule (ICAM)-1 was measured using eosinophil peroxidase
assays. The generation of eosinophil superoxide anion (O2) was examined based on the superoxide
dismutase-inhibitable reduction of cytochrome C. Eosinophil-derived neurotoxin (EDN) release was
evaluated by ELISA as a marker of degranulation.
Results: Neither formoterol nor salbutamol suppressed the spontaneous adhesion of eosinophils to
ICAM-1. However, when eosinophils were activated by IL-5, LTD4, or IP-10, formoterol, but not salbu-
tamol, suppressed the adhesion to ICAM-1. Formoterol also suppressed IL-5, LTD4, or IP-10 induced
eosinophil O2 generation or EDN release.
Conclusions: These ﬁndings suggest that formoterol, but not salbutamol, suppresses eosinophil functions
enhanced by IL-5, LTD4, or IP-10. As these factors are involved in the development of asthma exacer-
bation, our results strongly support the hypothesis that administration of formoterol is a novel strategy
for treating asthma exacerbation.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Eosinophils play important roles in the pathophysiology of
asthma through the release of a variety of inﬂammatory mediators
including major basic protein, cysteinyl leukotrienes (cysLTs),ry Medicine, Allergy Center,
ma-cho, Iruma-gun, Saitama
kagome).
ety of Allergology.
rgology. Production and hosting by Elsereactive oxygen species, and cytokines.1,2 Eosinophils are also
involved in the development of asthma exacerbation. For example,
Green et al. reported that a treatment strategy directed at
normalization of the ratio of eosinophils in induced sputum re-
duces asthma exacerbation.3 Among T helper (Th) 2 cytokines,
interleukin (IL)-5 is a well-recognized mediator in eosinophilic
inﬂammation,4 and the in vitro effects on eosinophils include pro-
longation of eosinophil survival and modiﬁcation of their func-
tions.5,6 Recent studies suggested that in asthmatics with persistent
sputum eosinophilia, treatment with anti-IL-5 mAb reduced
asthma exacerbations and the requirement of systemicvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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development of asthma exacerbation.
CysLTs, such as LTC4, LTD4, and LTE4, also contribute to the
accumulation of eosinophils in the tissues of asthmatic airways. We
have reported that LTD4 up-regulates the expression of b2 integrins
on human eosinophils in vitro and augments eosinophil adhesion.10
We also reported that LTD4 directly induces transendothelial
migration, superoxide anion (O2) generation, and degranulation.11
In fact, administration of cysLT1 receptor antagonists reduces the
number of eosinophils in sputum or blood in asthma patients12,13
and the frequency of asthma exacerbation in children.14 There-
fore, suppression of IL-5 (or Th2)-mediated or cysLT-mediated
eosinophilic inﬂammation could be a useful strategy for inhibit-
ing asthma exacerbation.
Acute respiratory infections are a major cause of asthma exac-
erbation.15,16 The role of IFN-g-inducible protein of 10 kDa (IP-10) in
virus-induced asthma exacerbation has been highlighted.17e19 We
reported that IP-10 up-regulates eosinophil functions such as
adhesion and O2 generation through CXC chemokine receptor
(CXCR) 3 and b2 integrin.20 We also reported that IP-10 induces
degranulation and produces a number of cytokines/chemokines.20
Therefore, during virus-induced asthma exacerbation IP-10 could
directly activate the function of eosinophils in the airway.
b2-adrenoreceptor agonists, such as formoterol and salbutamol,
are used to treat asthma exacerbation. Among these drugs, a
combination of formoterol and budesonide, especially when used
as reliever therapy, suppressed the rate of moderate or severe
excerbation,21e23 suggesting that formoterol may have other
functions in addition to its bronchodilating effect. To date, whether
b2-adrenoreceptor agonists are capable of suppressing eosinophilic
inﬂammation remains unknown. Some reports suggest that b2-
adrenoreceptor agonists suppress the function of mast cells,24,25
neutrophils,26e30 eosinophils,31e33 and T cells,34 although they are
still controversial.35e38 However, the effect of formoterol or sal-
butamol on the function of eosinophils, particularly eosinophils
activated by IL-5, cysLTs, or IP-10, has not been fully established.
The initial steps of eosinophil accumulation in the asthmatic
airway are adhesion to and subsequent transmigration across
endothelial cells. Therefore, interaction between eosinophils and
adhesion molecules would contribute to the development of
airway inﬂammation in bronchial asthma. In this study, we exam-
ined whether formoterol or salbutamol could modify eosinophil
functions such as adhesiveness, activated by IL-5, cysLTs, or IP-10.
We found that formoterol, but not salbutamol, suppressed eosin-
ophil adhesion to intercellular cell adhesion molecule (ICAM)-1
when eosinophils were stimulated with IL-5, cysLTs, or IP-10. We
also found that formoterol suppressed the IL-5, LTD4, or IP-10-
induced eosinophil O2 generation or degranulation.
Methods
Preparation of eosinophils
Eosinophils were isolated from peripheral blood collected from
non-atopic healthy donors with a peripheral blood differential
eosinophil count of <5%. The numbers of males and females,
ranging in age from 21 to 59 years, were comparable among the
donors. We received approval from the Ethical Committee of Sai-
tama Medical University, and informed consent was obtained
before collection of each blood sample. Eosinophils were isolated
by negative selection using immunomagnetic beads, as
described.10,11,20,39,40 Over 98% of the cells were eosinophils, as
determined by morphologic criteria using May-Grünwald-Giemsa
staining. Eosinophil viability was >99%, as determined by Trypanblue dye exclusion. Eosinophils were resuspended in Hank's
balanced salt solution (HBSS) supplemented with gelatin to a ﬁnal
concentration of 0.1% (HBSS/gel).
Eosinophil adhesion assay
Eosinophil adhesion to recombinant human (rh)-ICAM-1-
coated plates was assessed based on the residual eosinophil
peroxidase (EPO) activity of adherent eosinophils, as
described.10,11,20,39,40 Eosinophils were pre-incubated with for-
moterol (10 nM/100 nM/1000 nM) or salbutamol (10 nM/100 nM/
1000 nM) at 37 C for 15 min. The eosinophils (100 ml of
1  105 cells/ml in HBSS/gel) were then incubated with or without
IL-5 (100 pM), LTD4 (100 pM), or IP-10 (100 nM) in rh-ICAM-1-
coated plates at 37 C for 20 min. The plates were washed with
HBSS and 100 ml of HBSS/gel was then added to thewells. Standards
comprised of 100 ml of serially diluted cell suspensions (1  103,
3  103, 1  104, 3  104, and 1  105 cells/ml) were added to the
empty wells. The EPO substrate (1 mM o-phenylenediamine,
1 mM H2O2, and 0.1% Triton X-100 in Tris buffer, pH 8.0) was then
added to all wells and the plates were incubated for 30 min at room
temperature. The reaction was stopped by adding 20 ml of
4 M H2SO4 and absorbance was measured at 490 nm. Each exper-
iment was performed in quadruplicate using eosinophils from a
single donor, and the percentage eosinophil adhesion was deter-
mined from mean values that were calculated from log dose
response curves. Eosinophil viability after incubation was >98%, as
determined by Trypan blue dye exclusion.
Eosinophil O2
 generation
Eosinophil O2 generation was measured in 96-well plates
(Corning, NY, USA) as described based on the superoxide dismutase
(SOD)-inhibitable reduction of cytochrome C.11,20 We initially
added SOD (0.2 mg/ml in HBSS/gel; 20 ml) to SOD control wells and
then HBSS/gel to all wells to bring the ﬁnal volume to 100 ml. The
eosinophil density was adjusted to 1.25  106 cells/ml of HBSS/gel
mixed 4:1 with cytochrome C (12 mg/ml of HBSS/gel), and 100 ml of
eosinophil suspension was then added to all wells. After treatment
with formoterol and stimulation with IL-5, LTD4, or IP-10, the
absorbance of the cell suspensions in the wells was measured at
550 nm in an Immuno-Mini (NJ-2300; Japan Intermed, Tokyo,
Japan), followed by repeated measurements over the next 240 min.
The plates were incubated in a 5% CO2 incubator at 37 C between
measurements. Each reaction was evaluated in duplicate against
the control reaction inwells containing 20 mg/ml of SOD. The results
were adjusted for a 1-ml reaction volume, and O2 generation was
calculated at an extinction coefﬁcient of 21.1 mM-1 cm1, as nano-
moles of cytochrome C reduced per 1.0  106 cells/ml minus the
SOD control. The maximum value during the incubation time was
examined to evaluate the effects of various factors on eosinophil O2
generation. Cell viability, determined by Trypan blue exclusion at
the end of each experiment, remained at 95% after a 240-min in-
cubation with the activator.
Eosinophil degranulation
Eosinophils (1  106 cells/ml) in 96-well plates were incubated
for the 240 min that were required for measurement of O2 gener-
ation, and were then immediately centrifuged (700 g) at 4 C for
15 min. Recovered cell-free supernatants were subjected to
eosinophil-derived neurotoxin (EDN) analysis, as described previ-
ously.11,20 Levels of EDN were quantiﬁed using ELISA kits (Medical
and Biological Laboratory, Nagoya, Japan).
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Values are expressed as means ± SEM. Results were compared
using a one-way factorial analysis of variance (ANOVA) with
Tukey's test for multiple comparisons. Values of P < 0.05 were
considered statistically signiﬁcant.
Results
Effect of formoterol or salbutamol on spontaneous adhesion of
eosinophils to ICAM-1
The effect of formoterol or salbutamol on spontaneous eosino-
phil adhesion to ICAM-1 was studied. Eosinophils were incubated
with formoterol (10 nM/100 nM/1000 nM) or salbutamol (10 nM/
100 nM/1000 nM) and eosinophil adhesion to rh-ICAM-1 was
measured using residual EPO assays. In the absence of eosinophil
activators, it was found that formoterol or salbutamol did not
modify the adhesiveness of eosinophils to ICAM-1 (Fig. 1A, B). The
viability of eosinophils after treatment of formoterol or salbutamol
was more than 98%.
Effect of formoterol or salbutamol on eosinophil adhesion to ICAM-1
enhanced by IL-5
The effects of formoterol or salbutamol on IL-5-stimulated
eosinophil adhesion to ICAM-1 were assessed because IL-5 plays
important roles in the development of Th2-mediated eosinophilic
inﬂammation.4e9 Eosinophils were pre-incubated with formoterol
(10 nM/100 nM/1000 nM) or salbutamol (10 nM/100 nM/1000 nM)
for 15 min, stimulated with IL-5 (100 pM), and adhesion to rh-
ICAM-1 was evaluated. At 100 pM, IL-5 enhanced eosinophil
adhesiveness to ICAM-1 (Fig. 2A, B). Formoterol (1000 nM) signif-
icantly suppressed IL-5-stimulated eosinophil adhesion to ICAM-1
(Fig. 2A; medium [without formoterol (FOR)] 21.0 ± 1.1%, FOR
(1000 nM) 15.4 ± 0.6%; P < 0.05), although 10 nM or 100 nMFig. 1. Effect of formoterol or salbutamol on spontaneous eosinophil adhesiveness to ICAM
formoterol (10 nM/100 nM/1000 nM) (A) or salbutamol (10 nM/100 nM/1000 nM) (B) at 37 
EPO assays. Data are shown as means ± SEM of 6 experiments using cells from different dformoterol did not suppress adhesion [FOR (10 nM) 19.1 ± 1.2%, FOR
(100 nM) 18.0 ± 1.1%]. In contrast, salbutamol (10e1000 nM) did
not suppress eosinophil adhesion [Fig. 2B; medium (without sal-
butamol (SAL)] 22.9 ± 2.2%, SAL (10 nM) 20.4 ± 1.7%, SAL (100 nM)
21.3 ± 1.3%, SAL (1000 nM) 20.6 ± 1.5%; not signiﬁcant). As for pre-
incubation time, 15 or 30 min treatment of eosinophils with for-
moterol suppressed IL-5-induced adhesion although no pre-
incubation (simultaneous administration of formoterol) did not
suppress it (Fig. 2C). So we pre-incubated eosinophils with b2-
adrenoreceptor agonists for 15 min before addition of activator in
the following experiments.
Effect of formoterol or salbutamol on eosinophil adhesion to ICAM-1
enhanced by LTD4
LTD4 plays an important role in the development of eosinophilic
inﬂammation,10e14 and the effects of formoterol or salbutamol on
LTD4-stimulated eosinophil adhesion to ICAM-1 were assessed. As
we previously reported,10 100 pM LTD4 enhanced the adhesiveness
of eosinophils to ICAM-1 (Fig. 3A, B). Formoterol (1000 nM)
signiﬁcantly suppressed the eosinophil adhesion enhanced by LTD4
[Fig. 3A; medium (without FOR) 16.7 ± 1.3%, FOR (1000 nM)
9.4 ± 1.0%; P < 0.05]. In contrast, salbutamol did not suppress
eosinophil adhesion [Fig. 3B; medium (without SAL) 15.1 ± 1.7%,
SAL (1000 nM) 13.3 ± 1.3%; not signiﬁcant].
Effect of formoterol or salbutamol on eosinophil adhesion to ICAM-1
enhanced by IP-10
The effects of formoterol or salbutamol on IP-10-stimulated
eosinophil adhesion to ICAM-1 were studied because IP-10 plays
an important role in the development virus-induced asthma.17e19
As we previously reported,20 IP-10 (100 nM) enhanced the adhe-
siveness of eosinophils to ICAM-1 (Fig. 4A, B). Formoterol
(100e1000 nM) signiﬁcantly suppressed IP-10-stimulated eosino-
phil adhesion to ICAM-1 [Fig. 4A; medium (without FOR)-1. Eosinophils (100 ml of 1  105 cell/ml in HBSS/gel) were incubated with or without
C for 15 min. The adhesiveness of eosinophils to rh-ICAM-1 was assessed using residual
onors.
Fig. 2. Effect of formoterol or salbutamol on eosinophil adhesiveness to ICAM-1 enhanced by IL-5. Eosinophils were pre-incubated with formoterol (10 nM/100 nM/1000 nM) (A) or
salbutamol (10 nM/100 nM/1000 nM) (B) for 15 min, and then stimulated with IL-5 (100 pM). The adhesiveness of eosinophils to rh-ICAM-1 was assessed using residual EPO assays.
Data are shown as means ± SEM of 6 experiments using cells from different donors. **P < 0.01 vs. eosinophil adhesion without IL-5 (control). #P < 0.05 vs. eosinophil adhesion by IL-
5 without formoterol. (C) Effect of pre-incubation time of formoterol on eosinophil adhesion. Eosinophils were pre-incubated with formoterol (1000 nM) for 0 (no pre-incubation),
15, or 30 min, and then stimulated with IL-5 (100 pM). The adhesiveness of eosinophils to rh-ICAM-1 was assessed (n ¼ 4). The adhesion of eosinophils observed in response to IL-5
without formoterol treatment was used as a control (100%). ##P < 0.01 or ###P < 0.001 vs. eosinophil adhesion by IL-5 without formoterol.
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P < 0.01, respectively.]. Conversely, salbutamol did not suppress IP-
10-stimulated eosinophil adhesion [Fig. 4B; medium (without SAL)
11.0 ± 1.8%, SAL (1000 nM) 9.6 ± 1.6%; not signiﬁcant]. We also
examined the effect of pre-incubation time of formoterol on IP-10-
induced eosinophil adhesion. Pre-incubation of formoterol for
more than 15 min was needed to suppress IP-10-induced eosino-
phil adhesion (Fig. 4C).Fig. 3. Effect of formoterol or salbutamol on eosinophil adhesiveness to ICAM-1 enhanced by
salbutamol (10 nM/100 nM/1000 nM) (B) for 15 min, and then stimulated with LTD4 (100 pM
Data are shown as means ± SEM of 6 experiments using cells from different donors. *P < 0.0
LTD4 without formoterol.Effect of formoterol on eosinophil O2
 generation and degranulation
Finally, we examined whether formoterol could suppress other
functions of eosinophils such as O2 generation and degranulation.
Eosinophils were incubated with formoterol (1000 nM), stimulated
with IL-5 (100 pM), LTD4 (100 pM), or IP-10 (100 nM), and then
eosinophil O2 generation and EDN release were measured. For-
moterol (1000 nM) signiﬁcantly suppressed IL-5, LTD4, or IP-10-LTD4. Eosinophils were pre-incubated with formoterol (10 nM/100 nM/1000 nM) (A) or
). The adhesiveness of eosinophils to rh-ICAM-1 was assessed using residual EPO assays.
5 vs. eosinophil adhesion without LTD4 (control). #P < 0.05 vs. eosinophil adhesion by
Fig. 4. Effect of formoterol or salbutamol on eosinophil adhesiveness to ICAM-1 enhanced by IP-10. Eosinophils were pre-incubated with formoterol (10 nM/100 nM/1000 nM) (A)
or salbutamol (10 nM/100 nM/1000 nM) (B) for 15 min, and then stimulated with IP-10 (100 nM). The adhesiveness of the eosinophils to rh-ICAM-1 was assessed using residual EPO
assays. Data are shown as means ± SEM of 6 experiments using cells from different donors. *P < 0.05 vs. eosinophil adhesion without IP-10 (control). ##P < 0.01 vs. eosinophil
adhesion by IP-10 without formoterol. (C) Effect of pre-incubation time of formoterol on eosinophil adhesion. Eosinophils were pre-incubated with formoterol (1000 nM) for 0 (no
pre-incubation), 15, or 30 min, and then stimulated with IP-10 (100 nM). The adhesiveness of eosinophils to rh-ICAM-1 was assessed (n ¼ 4). The adhesion of eosinophils observed
in response to IP-10 without formoterol treatment was used as a control (100%). #P < 0.05 vs. eosinophil adhesion by IP-10 without formoterol.
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5þ FOR 2.4 ± 0.3 nmol/million cells, LTD4 1.2 ± 0.1 nmol/million
cells, LTD4 þ FOR 0.5 ± 0.1 nmol/million cells, IP-10 1.1 ± 0.1 nmol/
million cells, IP-10 þ FOR 0.5 ± 0.1 nmol/million cells; P < 0.05,
respectively) or EDN release (Fig. 5B; IL-5 247.4 ± 7.1 ng/ml, IL-
5 þ FOR 134.9 ± 6.2 ng/ml, P < 0.01; LTD4 69.4 ± 4.6 ng/ml,
LTD4 þ FOR 33.2 ± 2.8 ng/ml, P < 0.05; IP-10 68.8 ± 5.4 ng/ml, IP-
10 þ FOR 26.1 ± 1.9 ng/ml, P < 0.05). Therefore, formoterol could
suppress overall functions of eosinophils including O2 generation
and degranulation, enhanced by IL-5, LTD4, or IP-10.Fig. 5. Effect of formoterol on eosinophil O2 generation and EDN release. Eosinophils were in
or IP-10 (100 nM). (A) The generation of eosinophil O2 was examined based on the SOD-inh
was measured at 550 nm, followed by repeated measurements over the next 240 min. The
various factors on eosinophil O2 generation. (B) EDN concentrations of cell-free supernatants
from different donors. *P < 0.05 and **P < 0.01 vs. control. #P < 0.05 and ##P < 0.01 vs. wDiscussion
In this study, we found that formoterol, but not salbutamol,
suppressed the adhesion of eosinophils to ICAM-1 following acti-
vation by IL-5, LTD4, or IP-10. However, in the absence of activa-
tor(s), neither formoterol nor salbutamol suppressed eosinophil
adhesion. We also found that formoterol suppressed the IL-5, LTD4,
or IP-10-induced eosinophil O2 generation or EDN release. As IL-5,
cysLTs, and IP-10 are involved in development of asthma exacer-
bation through eosinophilic inﬂammation and viral infection, ourcubated with formoterol (1000 nM) and stimulated with IL-5 (100 pM), LTD4 (100 pM),
ibitable reduction of cytochrome C. The absorbance of the cell suspensions in the wells
maximum value during the incubation time was examined to evaluate the effects of
were measured by ELISA. Data are shown as means ± SEM of 4 experiments using cells
ithout formoterol.
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effective strategy for treating asthma exacerbation via both its
bronchodilation and anti-inﬂammatory actions.
b2-adrenoreceptor agonists, especially short-acting beta ago-
nists, are thought to be an aggravating factor for eosinophilic
airway inﬂammation and airway hyperresponsiveness.38,41e44
However, several studies have suggested that formoterol may
have anti-inﬂammatory properties in vivo.45e49 For example, Kelly
et al. reported that addition of formoterol to budesonide therapy
suppressed the eosinophil count in sputum as compared to bude-
sonide alone.45 Maneechotesuwan et al. reported that formoterol
attenuated neutrophilic airway inﬂammation in asthma,46 while
Bowden et al. reported that formoterol inhibited neutrophil and
eosinophil adhesion to venules of rat trachea.47 Furthermore,
Whelan et al. reported that formoterol, but not salbutamol, sup-
pressed platelet activating factor (PAF)-induced eosinophil accu-
mulation in guinea-pig lung.48 As b2-adrenoreceptor receptors are
present on inﬂammatory cells, such as mast cells, monocytes,
neutrophils, eosinophils, and T-lymphocytes,24,49 formoterol can
affect these cells through activation of b2-adrenergic receptors
in vitro. For example, formoterol suppresses the release of hista-
mine from mast cells,24 and inhibits the function of neu-
trophils.26e28 However, there is little information about the effect
of formoterol on eosinophil function. In this context, Eda et al. re-
ported that formoterol at concentrations greater than 1 mM
inhibited PAF-induced eosinophil chemotaxis and degranulation.31
In the present study, we found that 1 mM formoterol inhibited
eosinophil adhesiveness enhanced by IL-5, LTD4, or IP-10 (Fig. 2e4).
Furthermore, 1 mM formoterol also suppressed IL-5, LTD4, or IP-10-
induced eosinophil O2 generation or EDN release (Fig. 5). Therefore,
1 mM formoterol appears to down-modulate the effector functions
of eosinophils. As for the involvement of b2-adrenergic receptor,
Bowden et al. reported that ICI-118551, a b2-adrenergic receptor
antagonist, restored the formoterol-induced suppression of eosin-
ophil or neutrophil adhesion to rat trachea.47 Therefore, we think
formoterol suppressed the function of eosinophils though b2-
adrenergic receptor although we have not examined the effect of
its antagonist in this study.
The exact mechanisms bywhich formoterol, but not salbutamol,
suppressed eosinophil adhesiveness or other functions remain
unknown. One possibility is that the differences in cyclic adenosine
30, 5'-monophosphate (cAMP) levels in eosinophils may affect their
functions. Kita et al. reported that pretreatment with a cAMP analog
or cAMP phosphodiesterase-inhibitors strongly inhibited
immunoglobulin-induced human eosinophil degranulation.50 They
also reported that cAMP accumulation is inversely correlated with
eosinophil degranulation, and that the time course of cAMP accu-
mulation closely paralleled that of inhibition of eosinophil
degranulation.50 As for neutrophils, formoterol increased cAMP
more than salbutamol,27,28 and suppressed neutrophil functions,
including O2 generation, LTB4 generation, and elastase release.27,28
Furthermore, increased cAMP levels in neutrophils inhibited their
adhesion.51 Formoterol also increased cAMP levels to a greater
degree than salbutamol in cultured rat cardiomyocytes.52 There-
fore, formoterol would increase the cAMP level in eosinophils to a
greater degree than salbutamol, thus suppressing eosinophil
functions, although we could not evaluate cAMP levels in
formoterol-stimulated and salbutamol-stimulated eosinophils in
this study. Other possibility is that greater intrinsic efﬁcacy and
higher receptor binding afﬁnity of formoterol53,54 may affect the
eosinophil adhesion or other functions. In this study, we compared
the effect of formoterol with that of salbutamol at same concen-
trations. Considering the difference of intrinsic efﬁcacy and higher
receptor binding afﬁnity, higher concentration of salbutamol may
suppress the eosinophil functions.Viral infections, in particular rhinovirus (RV), is a major cause
of asthma exacerbation.15 Recent evidence suggests that IP-10 is
involved in RV-induced asthma exacerbation.17e19 For example,
RV infection induces bronchial epithelial cells to produce IP-10
in vitro and in vivo,17 and serum IP-10 concentrations are spe-
ciﬁcally increased in RV-induced asthma.19 Furthermore,
increased levels of IP-10 correlate with disease severity during
RV-induced exacerbation. These data suggest that IP-10 is likely
to play a role in the pathogenesis of virus-induced asthma
exacerbation. We previously reported that IP-10 up-regulates the
effector functions of eosinophils such as adhesiveness, O2 gen-
eration, degranulation, and cytokine/chemokine production.20
ICAM-1 is an adhesion molecule that plays an important role in
inﬂammatory cell recruitment, as well as being a cellular receptor
for the majority of RV-As and all RV-Bs.55 Furthermore, RV
infection increases ICAM-1 expression on epithelial cells,56,57 and
eosinophil adhesion to ICAM-1 could activate eosinophil func-
tions.58,59 Moreover, cysLTs are also increased in the airway
during virus-induced asthma.60,61 For example, van Schaik et al.
reported increased production of cysLTs in virus-induced
wheezing.60 Matsuse et al. reported that parainﬂuenza virus 3
infection was associated with a signiﬁcant increase in sputum
cysLTs during the acute phase of mild asthma exacerbation.61
Therefore, IP-10, ICAM-1, and cysLTs are all up-regulated in
viral or RV-induced asthma, thereby activating eosinophil func-
tion in the airway. In this study, formoterol was shown to sup-
press the adhesiveness of eosinophils enhanced by IP-10 or LTD4
and by ICAM-1 (Fig. 3A, 4A). Furthermore, budesonide/formoterol
maintenance and reliever therapy was observed to reduce the
risk of severe cold-related exacerbations, but not the incidence of
colds, in asthmatics.62 Taken together, administration of for-
moterol could be a novel strategy for treating virus-induced
asthma by suppressing the function of eosinophils activated by
IP-10, LTD4, and ICAM-1.
In this study, we have not examined the effect of formoterol on
the expression of adhesion molecules such as CD11b/CD18. How-
ever, we previously reported that LTD4 increased the expression of
CD11b/CD18 on the eosinophil surface, and thus augmented the
eosinophil adhesion to ICAM-1.10 Furthermore, Anderson et al. re-
ported that formoterol suppressed the expression of adhesion
molecules (CR3; CD11b/CD18) of neutrophils.27 Taken together, we
think that formoterol suppressed the eosinophil adhesion to ICAM-
1 by suppressing the CD11b/CD18 expression on the eosinophil
surface.
One limitation in interpreting the ﬁndings of our study is that
there is little information about formoterol concentration in plasma
or airways. Campestrini et al. reported that the plasma concentra-
tion of formoterol reached approximately 300 pM after inhalation
of 90 mg of formoterol.63 Gravett et al. speculated that the local
concentration of formoterol is approximately 10 nM (assuming a
maximal single dose of 24 mg, lung deposition of 18.6%, and a tidal
volume of 500 ml).26 Although the actual concentration in the
airway is more difﬁcult to ascertain, the concentration of more than
1 mM in the inﬂammation cites seems to be hard to achieve after
formoterol treatment during asthma attack.
We have not examined the effect of salmeterol, another long-
acting beta agonist, in this study. However, some reports sug-
gested that salmeterol might also have an anti-inﬂammatory
property. For example, Ottonello et al. reported that salmeterol,
but not salbutamol, suppressed super oxide generation by neu-
trophils.30 Ezeamuzie et al. reported that salmeterol, but not sal-
butamol, suppressed IL-5 or PAF-induced activation of effector
functions of eosinophils such as adhesion, super oxide generation,
and degranulation.32 However, the relationship between the
elevation of cAMP and the inhibitory effect by salmeterol is not
T. Noguchi et al. / Allergology International 64 (2015) S46eS53S52clear,30 suggesting mechanisms other than increased cAMP levels
may play roles in salmeterol-mediated suppression of neutrophil or
eosinophil function.
In conclusion, we found that when eosinophils were activated
by IL-5, LTD4, or IP-10, formoterol, but not salbutamol, suppressed
the adhesion of eosinophils to ICAM-1. Furthermore, formoterol
suppressed the IL-5, LTD4, or IP-10-induced eosinophil O2 genera-
tion or degranulation. Therefore, administration of formoterol may
be a novel strategy for treating asthma exacerbation via its inhib-
itory effect on eosinophilic inﬂammation.
Acknowledgments
The authors thank Ms. Akemi Yokote for her excellent technical
assistance. This work was supported by grants from the Ministry of
Education, Culture, Sports, Science, and Technology (Japan, Grant
nos. 205591191, 21790783, and 24791004).
Conﬂict of interest
MN received honoraria from MSD, Torii Pharmaceutical and AstraZeneca. The
rest of the authors have no conﬂict of interest.
Authors' contributions
TN carried out the experiments, analyzed the data, and drafted the manuscript.
KN participated in direction of the study, analyzed the data, and wrote the manu-
script. TK and YU carried out the eosinophil experiments. TS and HN participated in
the data analyses. MN participated in direction of the study and edited the manu-
script. All authors read and approved the ﬁnal manuscript.
References
1. Gleich GJ. Mechanisms of eosinophil-associated inﬂammation. J Allergy Clin
Immunol 2000;105:651e63.
2. Weller PF. Human eosinophils. J Allergy Clin Immunol 2000;100:283e7.
3. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled
trial. Lancet 2002;360:1715e21.
4. Teran LM. Chemokines and IL-5: major players of eosinophil recruitment in
asthma. Clin Exp Allergy 1999;29:287e90.
5. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-
stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosino-
phils in vitro. Clin Exp Immunol 1991;85:312e6.
6. Yamaguchi Y, Hayashi Y, Sugama Y, Miura Y, Kasahara T, Kitamura S, et al.
Highly puriﬁed murine interleukin 5 (IL-5) stimulates eosinophil function and
prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med
1988;167:1737e42.
7. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E,
et al. Mepolizumab for prednisone-dependent asthma with sputum eosino-
philia. N Engl J Med 2009;360:985e93.
8. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al.
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med
2009;360:973e84.
9. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al.
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J
Med 2014;371:1198e207.
10. Nagata M, Saito K, Tsuchiya T, Sakamoto Y. Leukotriene D4 upregulates
eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin
Immunol 2002;109:676e770.
11. Saito K, Nagata M, Kikuchi I, Sakamoto Y. Leukotriene D4 and eosinophil
transendothelial migration, superoxide generation, and degranulation via
beta2 integrin. Ann Allergy Asthma Immunol 2004;93:594e600.
12. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on
surrogate inﬂammatory markers in corticosteroid-treated patients with
asthma. Am J Respir Crit Care Med 2003;167:1232e8.
13. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, et al.
Montelukast and ﬂuticasone compared with salmeterol and ﬂuticasone in
protecting against asthma exacerbation in adults: one year, double blind,
randomised, comparative trial. BMJ 2003;327:891.
14. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al.
Montelukast reduces asthma exacerbations in 2- to 5-year-old children with
intermittent asthma. Am J Respir Crit Care Med 2005;171:315e22.
15. Friedlander SL, Busse WW. The role of rhinovirus in asthma exacerbations.
J Allergy Clin Immunol 2005;116:267e73.
16. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK,
et al. The relationship between upper respiratory infections and hospital ad-
missions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154:
654e60.17. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D. Human airway epithelial
cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am
J Physiol Lung Cell Mol Physiol 2005;289:L85e95.
18. Korpi-Steiner NL, Valkenaar SM, Bates ME, Evans MD, Gern JE, Bertics PJ. Hu-
man monocytic cells direct the robust release of CXCL10 by bronchial epithelial
cells during rhinovirus infection. Clin Exp Allergy 2010;40:1203e13.
19. Wark PA, Bucchieri F, Johnston SL, Gibson PG, Hamilton L, Mimica J, et al. IFN-
g-induced protein 10 is novel biomarker of rhinovirus induced asthma exac-
erbation. J Allergy Clin Immunol 2007;120:586e93.
20. Takaku Y, Nakagome K, Kobayashi T, Hagiwara K, Kanazawa M, Nagata M. IFN-
g-inducible protein of 10 kDa upregulates the effector functions of eosinophils
through b2 integrin and CXCR3. Respir Res 2011;12:138.
21. Pauwels RA, L€ofdahl CG, Postma DS, Tattersﬁeld AE, O'Byrne P, Barnes PJ, et al.
Effect of inhaled formoterol and budesonide on exacerbations of asthma.
Formoterol and Corticosteroids Establishing Therapy (FACET) International
Study Group. N Engl J Med 1997;337:1405e11.
22. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budeso-
nide in combination with formoterol for reliever therapy in asthma exacer-
bations: a randomised controlled, double-blind study. Lancet 2006;368:
744e53.
23. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al.
Budesonide/formoterol combination therapy as both maintenance and reliever
medication in asthma. Am J Respir Crit Care Med 2005;171:129e36.
24. Johnson M. Effects of beta2-agonists on resident and inﬁltrating inﬂammatory
cells. J Allergy Clin Immunol 2002;110:S282e90.
25. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting in-
hibitor of inﬂammatory mediator release from human lung. Br J Pharmacol
1991;104:672e6.
26. Gravett CM, Theron AJ, Steel HC, Tintinger GR, Cockeran R, Feldman C, et al.
Interactive inhibitory effects of formoterol and montelukast on activated hu-
man neutrophils. Eur Respir J 2010;36:1417e24.
27. Anderson R, Theron AJ, Steel HC, Durandt C, Tintinger GR, Feldman C. The beta-
2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol,
effectively suppress the reactivity of human neutrophils in vitro. Mediat
Inﬂamm 2014;2014:105420.
28. Tintinger GR, Anderson R, Theron AJ, Ramaﬁ G, Ker JA. Comparison of the ef-
fects of selective and non-selective beta-adrenoreceptor agonists on the pro-
inﬂammatory activities of human neutrophils in vitro. Inﬂammation 2000;24:
239e49.
29. Kawashima A, Suzuki T, Nishihara F, Kobayashi T, Takaku Y, Nakagome K, et al.
Effect of formoterol on eosinophil trans-basement membrane migration
induced by interleukin-8-stimulated neutrophils. Int Arch Allergy Immunol
2013;161(Suppl 2):10e5.
30. Ottonello L, Morone P, Dapino P, Dallegri F. Inhibitory effect of salmeterol on
the respiratory burst of adherent human neutrophils. Clin Exp Immunol
1996;106:97e102.
31. Eda R, Sugiyama H, Hopp RJ, Okada C, Bewtra AK, Townley RG. Inhibitory ef-
fects of formoterol on platelet-activating factor induced eosinophil chemotaxis
and degranulation. Int Arch Allergy Immunol 1993;102:391e8.
32. Ezeamuzie CI, al-Hage M. Differential effects of salbutamol and salmeterol on
human eosinophil responses. J Pharmacol Exp Ther 1998;284:25e31.
33. Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E, et al. Additive blockade of
beta 2-integrin adhesion of eosinophils by salmeterol and ﬂuticasone propio-
nate. Eur Respir J 2004;23:511e7.
34. Hashimoto T, Kitamura N, Kobayashi N, Suko M, Kaminuma O, Mori A. Effect of
formoterol on allergen-induced cytokine synthesis by atopic asthmatics. Int
Arch Allergy Immunol 2007;143(s1):106e9.
35. Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, et al. Acti-
vation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic
agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol 2005;288:
L860e7.
36. Yukawa T, Ukena D, Kroegel C, Chanez P, Dent G, Chung KF, et al. Beta 2-
adrenergic receptors on eosinophils. Binding and functional studies. Am Rev
Respir Dis 1990;141:1446e52.
37. Mu~noz NM, Rabe KF, Vita AJ, McAllister K, Mayer D, Weiss M, et al. Paradoxical
blockade of beta adrenergically mediated inhibition of stimulated eosinophil
secretion by salmeterol. J Pharmacol Exp Ther 1995;273:850e4.
38. Yamaguchi T, Soma T, Takaku Y, Nakagome K, Hagiwara K, Kanazawa M,
et al. Salbutamol modulates the balance of Th1 and Th2 cytokines by
mononuclear cells from allergic asthmatics. Int Arch Allergy Immunol 2010;
152(s1):32e40.
39. Kobayashi T, Takaku Y, Yokote A, Miyazawa H, Soma T, Hagiwara K, et al.
Interferon-b augments eosinophil adhesion inducing activity of endothelial
cells. Eur Respir J 2008;32:1540e7.
40. Soma T, Takaku Y, Kobayashi T, Hagiwara K, Kanazawa M, Uematsu K, et al.
Inhibitory effect of budesonide alone and in combination with formoterol on
IL-5 and RANTES production from mononuclear cells. Int Arch Allergy Immunol
2008;146(s1):22e7.
41. Gauvreau GM, Jordana M, Watson RM, Cockroft DW, O'Byrne PM. Effect of
regular inhaled albuterol on allergen-induced late responses and sputum
eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997;156:
1738e45.
42. Swystun VA, Gordon JR, Davis EB, Zhang X, Cockcroft DW. Mast cell tryptase
release and asthmatic responses to allergen increase with regular use of sal-
butamol. J Allergy Clin Immunol 2000;106:57e64.
T. Noguchi et al. / Allergology International 64 (2015) S46eS53 S5343. Lindqvist A, Karjalainen EM, Laitinen LA, Kava T, Altraja A, Pulkkinen M,
et al. Salmeterol resolves airway obstruction but does not possess anti-
eosinophil efﬁcacy in newly diagnosed asthma: a randomized, double-
blind, parallel group biopsy study comparing the effects of salmeterol, ﬂu-
ticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol
2003;112:23e8.
44. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Po-
tential masking effects of salmeterol on airway inﬂammation in asthma. Am J
Respir Crit Care Med 1998;158:924e30.
45. Kelly MM, O'Connor TM, Leigh R, Otis J, Gwozd C, Gauvreau GM, et al. Effects of
budesonide and formoterol on allergen-induced airway responses, inﬂamma-
tion, and airway remodeling in asthma. J Allergy Clin Immunol 2010;125:
349e56.
46. Maneechotesuwan K, Essilﬁe-Quaye S, Meah S, Kelly C, Kharitonov SA,
Adcock IM, et al. Formoterol attenuates neutrophilic airway inﬂammation in
asthma. Chest 2005;128:1936e42.
47. Bowden JJ, Sulakvelidze I, McDonald DM. Inhibition of neutrophil and eosin-
ophil adhesion to venules of rat trachea by beta 2-adrenergic agonist for-
moterol. J Appl Physiol 1994;77:397e405.
48. Whelan CJ, Johnson M, Vardey CJ. Comparison of the anti-inﬂammatory
properties of formoterol, salbutamol and salmeterol in guinea-pig skin and
lung. Br J Pharmacol 1993;110:613e8.
49. Barnes PJ. Beta-adrenoceptors on smooth muscle, nerves and inﬂammatory
cells. Life Sci 1993;52:2101e9.
50. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Regulation of Ig-induced
eosinophil degranulation by adenosine 30 ,50-cyclic monophosphate.
J Immunol 1991;146:2712e8.
51. Bloemen PG, van den Tweel MC, Henricks PA, Engels F, Kester MH, van de
Loo PG, et al. Increased cAMP levels in stimulated neutrophils inhibit their
adhesion to human bronchial epithelial cells. Am J Physiol 1997;272:L580e7.
52. Freyss-Beguin M, Griffaton G, Lechat P, Picken D, Quennedey MC, Rouot B, et al.
Comparison of the chronotropic effect and the cyclic AMP accumulation
induced by beta 2-agonists in rat heart cell culture. Br J Pharmacol 1983;78:
717e23.53. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efﬁ-
cacy: measurement and clinical signiﬁcance. Am J Respir Crit Care Med
2002;165:1353e8.
54. Johnson M. Pharmacology of long-acting beta-agonists. Ann Allergy Asthma
Immunol 1995;75:177e9.
55. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, et al. The major
human rhinovirus receptor is ICAM-1. Cell 1989;56:839e47.
56. Papi A, Johnston SL. Rhinovirus infection induces expression of its own re-
ceptor intercellular adhesion molecule1 (ICAM-1) via increased NF-kb-medi-
ated transcription. J Biol Chem 1999;274:9707e20.
57. Grünberg K, Sharon RF, Hiltermann TJ, Brahim JJ, Dick EC, Sterk PJ, et al.
Experimental rhinovirus 16 infection increases intercellular adhesion
molecule-1 expression in bronchial epithelium of asthmatics regardless of
inhaled steroid treatment. Clin Exp Allergy 2000;30:1015e23.
58. Nagata M, Sedgwick JB, Bates ME, Kita H, Busse WW. Eosinophil adhesion to
vascular cell adhesion molecule-1 activates superoxide anion generation.
J Immunol 1995;155:2194e202.
59. Nagata M, Sedgwick JB, Kita H, Busse WW. Granulocyte macrophage colony-
stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil
function. Am J Respir Cell Mol Biol 1998;19:158e66.
60. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver 2nd RC, Welliver RC.
Increased production of IFN-gamma and cysteinyl leukotrienes in virus-
induced wheezing. J Allergy Clin Immunol 1999;103:630e6.
61. Matsuse H, Kondo Y, Saeki S, Nakata H, Fukushima C, Mizuta Y, et al. Naturally
occurring parainﬂuenza virus 3 infection in adults induces mild exacerbation of
asthma associated with increased sputum concentrations of cysteinyl leuko-
trienes. Int Arch Allergy Immunol 2005;138:267e72.
62. Reddel HK, Jenkins C, Quirce S, Sears MR, Bateman ED, O'Byrne PM, et al. Effect
of different asthma treatments on risk of cold-related exacerbations. Eur Respir
J 2011;38:584e93.
63. Campestrini J, Lecaillon JB, Godbillon J. Automated and sensitive method for
the determination of formoterol in human plasma by high-performance liquid
chromatography and electrochemical detection. J Chromatogr B Biomed Sci Appl
1997;704:221e9.
